Articles

7 Questions: Emma Greenwood on advancing research in cancer

3rd August 2015

7 Questions: Emma Greenwood on advancing research in cancerEmma Greenwood

pharmaphorum spoke to the head of policy development at the influential cancer charity about how it is supporting research and increasing the numbers who survive the disease.What prompted you to... Read more

Healthcare communications: hit the reset button

31st July 2015

Healthcare communications: hit the reset button Christian Gardner

In this social media age, when ePatients and bloggers can have the same influence as trade journalists, is it time to abandon traditional methods and apply a fresh approach?What influences... Read more

Should DTC marketers put away their marketing hats?

30th July 2015

Should DTC marketers put away their marketing hats?Richard Meyer

Pharma companies need to put themselves in the patient's shoes and provide clear, helpful content at what is often a worrying and stressful time. Richard Meyer offers some useful pointers.In... Read more

Top tips for writing the best benefit-risk reports

29th July 2015

Top tips for writing the best benefit-risk reportsSeema Jaitly

It is important to stay abreast of the latest requirements in pharmacovigilance in order to meet the needs of the regulators. Here, Seema Jaitly cuts through the confusion to provide... Read more

News

Roche's Perjeta cleared for early use in breast cancer

3rd August 2015

Roche's Perjeta cleared for early use in breast cancerPhil Taylor

Breast cancer patients in the EU could get treatment with Roche's Perjeta earlier in the course of the disease after the drug was approved for a new indication.The European Medicines... Read more

A yes for Gilead, AbbVie and BMS hepatitis drugs, but NICE restricts u…

29th July 2015

A yes for Gilead, AbbVie and BMS hepatitis drugs, but NICE restricts useAndrew McConaghie

NICE has given the green light to three new hepatitis C treatments, but has specified precisely which patients can receive which drugs, based on the patient's genotypes, and the progression... Read more

NICE diabetes guidelines still don’t add up, say doctors and pharma co…

29th July 2015

NICE diabetes guidelines still don’t add up, say doctors and pharma companyAndrew McConaghie

NICE has re-drafted new guidelines for type 2 diabetes treatments after a major backlash from doctors – but critics say the second attempt is still badly flawed.The UK's National Institute... Read more

Sanofi and Regeneron play catch-up in immunotherapy with $1bn alliance

28th July 2015

Sanofi and Regeneron play catch-up in immunotherapy with $1bn allianceAndrew McConaghie

In an attempt to catch up with leaders in the red-hot field of cancer immunotherapy, Sanofi and Regeneron have announced a major new research partnership.Sanofi is to make a huge... Read more

Audio & Video

Available on demand: Changing behaviour:…

BrightTALK holding slide 4 22June

 

Understanding your customers is fundamental to effective communication. Current segmentation strategies draw on ever more detailed information... View more

Available on demand: Effectively using r…

Zephyr-Webinar-Holding-Slide-2

 

Life sciences companies need to make better use of the insights that real-world data (RWD) can provide in order to improve market... View more

Available on demand: Exclusive debate/we…

Ashfield-PP-HS1

 

The way that physicians want and need to consume information has changed dramatically over recent years and continues to evolve rapidly. Working in... View more

Being Patient-centric is being Family-ce…

 

Cancer survivor and patient opinion leader Andrew Schorr and his wife Esther Schorr discuss how families should be involved in decision-making around care for patients.... View more

White Papers

Successful biopharma product launches de…

Successful biopharma product launches depend upon market insights – driving competitive advantage through innovationChristian Marcazzo & Robin Munro

A major competitive advantage can be gained by companies that unlock the value hidden in the vast quantity of healthcare data available today – particularly that presented by real-world data.View info

Optimising patient outcomes through phys…

Optimising patient outcomes through physician educationDr James Quekett

Physician education is undergoing a massive change as the volume of advances in therapies and practices increases and the use of digital channels facilitates new forms of scientific exchange. This white... View info

Is pharma brand marketing dead?

Is pharma brand marketing dead?Mark Sales, Fabrice Bourg & Richard Goosey

This comprehensive supplement brings together a series of articles, insights and discussions produced by Kantar Health in order to help stimulate debate and fresh thinking about the future of pharmaceutical... View info

Improved health and wellbeing in COPD

Improved health and wellbeing in COPDAna Maria Arboleda, Clare Maloney & Prof John Weinman

Chronic obstructive pulmonary disease (COPD) is a progressive and debilitating disorder, which, as it progresses, places a significant burden on individuals and those caring for them. This is not only... View info

Further News & Articles

Teva's $40bn Allergan acquisition adds twist to merger drama

The merger merry-go-round continues to spin, although the three-way drama involving Teva Pharmaceutical Industri... Read more

News

Personal perspective: living with hepatitis C

On #WorldHepatitisDay we highlight a personal account from a woman in the US diagnosed with hepatitis C and how t... Read more

Articles

Europe fast tracks rival myeloma drugs from Takeda, Abbvie and BMS

Two rival treatments for multiple myeloma have been granted 'accelerated assessment' by Europe's medicines re... Read more

News

Malaria vaccine and Sanofi's Praluent lead CHMP opinions

The latest set of recommendations by European Medicines Agency are dominated by positive opinions for the world'... Read more

News

Can treatment as prevention work for hepatitis C?

The advent of better drugs has helped increase interest in treatment as prevention for hepatitis C (HCV). With tomor... Read more

Articles

Prostate cancer breakthrough must wait for publication, says NHS England

Groundbreaking, low-cost treatment which dramatically extends the lives of prostate cancer patients won't be recommended... Read more

News